JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


First published online September 15, 2008, 10.2967/jnumed.108.053694
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.108.053694v1
49/10/1579    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benz, M. R.
Right arrow Articles by Weber, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benz, M. R.
Right arrow Articles by Weber, W. A.
Journal of Nuclear Medicine Vol. 49 No. 10 1579-1584
© 2008 by Society of Nuclear Medicine

doi: 10.2967/jnumed.108.053694

Clinical Investigation

Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas

Matthias R. Benz1, Martin S. Allen-Auerbach1, Fritz C. Eilber1,2, Hui J.J. Chen3, Sarah Dry4, Michael E. Phelps1, Johannes Czernin1 and Wolfgang A. Weber1,5

1 Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California; 2 Division of Surgical Oncology, University of California Los Angeles, Los Angeles, California; 3 Department of Radiology, University of California Los Angeles, Los Angeles, California; 4 Department of Pathology, University of California Los Angeles, Los Angeles, California; and 5 Abteilung Nuklearmedizin, University of Freiburg, Freiburg, Germany

Correspondence: For correspondence or reprints contact: Wolfgang Weber, Abteilung Nuklearmedizin University of Freiburg, Hugstetterstrasse 55, 79106 Freiburg, Germany. E-mail: wolfgang.weber{at}uniklinik-freiburg.de

By allowing simultaneous measurements of tumor volume and metabolic activity, integrated PET/CT opens up new approaches for assessing tumor response to therapy. The aim of this study was to determine whether combined assessment of tumor volume and metabolic activity improves the accuracy of 18F-FDG PET for predicting histopathologic tumor response in patients with soft-tissue sarcomas. Methods: Twenty patients with locally advanced high-grade soft-tissue sarcoma (10 men and 10 women; mean age, 49 ± 17 y) were studied by 18F-FDG PET/CT before and after preoperative therapy. CT tumor volume (CTvol) was measured by delineating tumor borders on consecutive slices of the CT scan. Mean and maximum 18F-FDG standardized uptake value within this volume (SUVmean and SUVmax, respectively) were determined. Two indices of total lesion glycolysis (TLG) were calculated by multiplying tumor volume by SUVmean (TLGmean) and SUVmax (TLGmax). Changes in CTvol, SUVmean, SUVmax, TLGmean, and TLGmax after chemotherapy were correlated with histopathologic tumor response (≥95% treatment-induced tumor necrosis). Accuracy for predicting histopathologic response was compared by receiver-operating-characteristic (ROC) curve analysis. Results: Baseline SUVmax, SUVmean, CTvol, TLGmean, and TLGmax were 11.22 g/mL, 2.84 g/mL, 544.1 mL, 1,619.8 g, and 8852.9 g, respectively. After neoadjuvant therapy, all parameters except CTvol showed a significant decline ({Delta}SUVmax = –51%, P < 0.001; {Delta}SUVmean = –40%, P < 0.001; {Delta}CTvol = –14%, P = 0.37; {Delta}TLGmean = –44%, P = 0.006; and {Delta}TLGmax = –54%, P = 0.001). SUV changes in histopathologic responders (n = 6) were significantly more pronounced than those in nonresponders (n = 14) (P = 0.001). Histopathologic response was well predicted by changes in SUVmean and SUVmax (area under ROC curve [AUC] = 1.0 and 0.98, respectively) followed by TLGmean (AUC = 0.77) and TLGmax (AUC = 0.74). In contrast, changes in CTvol did not allow prediction of treatment response (AUC = 0.48). Conclusion: In this population of patients with sarcoma, TLG was less accurate in predicting tumor response than were measurements of the intratumoral 18F-FDG concentration (SUVmax, SUVmean). Further evaluation of TLG in larger patient populations and other tumor types is necessary to determine the value of this conceptually attractive parameter for assessing tumor response.

Key Words: sarcoma • PET/CT • 18F-FDG • treatment monitoring • multimodality imaging

Guest Editor: Barry Siegel, Mallinckrodt Institute of Radiology

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  



This article has been cited by other articles:


Home page
JNMHome page
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2008 by the Society of Nuclear Medicine.